Related Experiment Video
Updated: May 21, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Novel Pyrido[4,3‑d]pyrimidine Derivatives as Kirsten Rat Sarcoma (KRAS) G12C Potential Inhibitors
Ruihu Song1, Steven H Liang1,2
1Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
None:
This highlight describes novel substituted 2-((tetrahydro-1H-pyrrolizin-7a-(5H)-yl)-methoxy)-pyrido-[4,3-d]-pyrimidine derivatives as potential inhibitors for Kirsten Rat Sarcoma (KRAS) G12C, which is extensively expressed across a variety of cancers. The patent provides detailed description of the preparation routes, methods of use, biological activity evaluations, and pharmaceutical compositions.
Related Concept Videos
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Ras Gene
Ras is a superfamily...
